Anavex Life Sciences Corp (AVXL)

[falconer66a]

More positive Anavex developments.

The ability of Anavex 2-73 to safely, effectively treat an ever-expanding list of Central Nervous System diseases is further revealed by today’s corporate announcement:
http://ih.advfn.com/p.php?pid=nmona&article=74661505

Read the whole article. Count and list the number of CNS diseases for which Anavex 2-73 has shown efficacy. It’s not just Alzheimer’s or Parkinson’s.

I’ve done a bit of reading of technical papers investigating successful Anavex 2-73 treatment of animal-based analogues (transgenic, etc.) of human CNS diseases. That list is even bigger. Beyond CNS diseases are cancers, heart disease, psychiatric conditions, and more.

The safety and magnitude of Anavex 2-73 therapies (and later, perhaps equal or exceeding it by Anavex 3-71) are, as yet, virtually unrecognized by the general investment and scientific communities. Those communities continue to think Anavex 2-73 is but another, destined-to-fail beta amyloid target.

This willful ignorance, however, is not possessed by whatever parties Anavex principals are discussing with potential marketing collaborators. Behind closed doors, experts are fully aware of the revolutionary Anavex molecules, and will act appropriately. We don’t get to monitor those discussions, but the science and clinical data can be understood by a college freshman biology student. No real mystery; just new, unique, and unexpected facts.

And none of this is obscure to FDA officials monitoring Anavex’s progress. The Trump administration’s efforts to bring new drugs promptly to market set Anavex 2-73 in sharp focus, a perfect demonstration drug for this new initiative.

Let’s see how this plays out.